- Home
- USPH vs KURA Comparison
USPH vs KURA Comparison
Compare USPH & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USPH | KURA |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | 5500 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | USPH | KURA |
|---|---|---|
| Price | $78.34 | $12.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $101.67 | $25.56 |
| AVG Volume (30 Days) | 133.4K | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $780,990,000.00 | $67,482,000.00 |
| Revenue This Year | $10.62 | $28.28 |
| Revenue Next Year | $6.30 | $106.37 |
| P/E Ratio | $599.00 | ★ N/A |
| Revenue Growth | 16.33 | ★ 25.24 |
| 52 Week Low | $58.19 | $7.36 |
| 52 Week High | $93.50 | $13.90 |
Technical Indicators
Market Signals| Indicator | USPH | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 50.99 |
| Support Level | $76.90 | $7.96 |
| Resistance Level | $79.92 | $12.27 |
| Average True Range (ATR) | 2.03 | 0.64 |
| MACD | -0.26 | -0.08 |
| Stochastic Oscillator | 37.66 | 24.09 |
Price Performance
Historical ComparisonAbout USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operate outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.